tumor-infiltrating lymphocytes

tu·mor-in·fil·trat·ing lym·pho·cytes (TIL, TILS),

(lim'fō-sītz),
lymphocytes collected from the site of a tumor and exposed to IL-2 in vitro to expand the population. When these cells are reinjected into the tumor-bearing host, they will specifically kill the tumor from which they originated.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
Tumor-infiltrating lymphocytes (TILs), which include B-cells, T-cells, and natural killer (NK) cells, are an important component in anti-tumor immune responses.
Developed using pathologist-verified antibodies, the panels can be mixed and matched to profile tumor-infiltrating lymphocytes, immune cell activation states and tissue architecture.
In order to explore the effect of artesunate on lymphocyte activity in the tumor microenvironment, we isolated the tumor-infiltrating lymphocytes from solid tumor samples of ovarian cancer in mice.
These lymphocytes were termed as tumor-infiltrating lymphocytes (TILs).
Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage and a favorable prognosis in operated small cell lung carcinoma.
The researchers then tested different tumor-infiltrating lymphocytes (TILs) from the patient to find those that recognized one or more of the mutated proteins.
Prognostic significance of programmed cell death ligand 1 (PD-L1), CD8+ tumor-infiltrating lymphocytes and p53 in non-small cell lung cancer: An immunohistochemical study.
Nikolaos Zacharakis, Ph.D., from the National Institutes of Health in Bethesda, Md., and colleagues present the case of a 49-year-old woman with chemorefractory hormone receptor-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes that were reactive against mutation versions of four proteins (SLC3A2, KIAA0368, CADPS2, and CTSB).
The potential synergies of RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) will be explored preclinically for the use in the treatment of cancer.

Full browser ?